$BCAX
Bicara Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000202365824000002 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.764M
YoY Change
% of Gross Profit
Research & Development $15.90M
YoY Change 130.43%
% of Gross Profit
Depreciation & Amortization $15.00K
YoY Change
% of Gross Profit
Operating Expenses $20.63M
YoY Change 116.45%
Operating Profit -$20.63M
YoY Change 116.45%
Interest Expense $3.147M
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.147M
YoY Change -123.63%
Pretax Income -$17.48M
YoY Change -23.48%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$17.48M -$12.51M
YoY Change -23.48% 68.75%
Net Earnings / Revenue
Basic Earnings Per Share -$1.60
Diluted Earnings Per Share -$1.60
COMMON SHARES
Basic Shares Outstanding 54.42M shares 10.90M shares
Diluted Shares Outstanding 10.90M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $520.8M
YoY Change
Cash & Equivalents $520.8M
Short-Term Investments
Other Short-Term Assets $756.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $521.5M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $130.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.115M
YoY Change
Total Long-Term Assets $2.659M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $521.5M
Total Long-Term Assets $2.659M
Total Assets $524.2M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.962M
YoY Change
Accrued Expenses $12.52M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.48M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.48M
Total Long-Term Liabilities $0.00
Total Liabilities $14.62M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$200.1M
YoY Change
Common Stock $7.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $509.6M -$160.1M
YoY Change
Total Liabilities & Shareholders Equity $524.2M
YoY Change

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024 Q1
OPERATING ACTIVITIES
Net Income -$17.48M -$12.51M
YoY Change -23.48% 68.75%
Depreciation, Depletion And Amortization $15.00K
YoY Change
Cash From Operating Activities -$17.22M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $8.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$8.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 334.1M
YoY Change
NET CHANGE
Cash From Operating Activities -17.22M
Cash From Investing Activities -8.000K
Cash From Financing Activities 334.1M
Net Change In Cash 316.9M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$17.22M
Capital Expenditures $8.000K
Free Cash Flow -$17.23M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 bcax Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7448000 usd
CY2023Q4 bcax Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6035000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1807000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1742000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1087000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
184000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
68000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
92000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0002023658
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1082
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1082
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-42271
dei Entity Registrant Name
EntityRegistrantName
BICARA THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2903745
dei Entity Address Address Line1
EntityAddressAddressLine1
116 Huntington Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 703
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
468-4219
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
BCAX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54415619 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
520758000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230440000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
756000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
633000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
521514000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
231073000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
130000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
202000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
414000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
613000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2115000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2094000 usd
CY2024Q3 us-gaap Assets
Assets
524173000 usd
CY2023Q4 us-gaap Assets
Assets
233982000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
308000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
285000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14481000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15085000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
137000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
372000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
14618000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
15474000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
367277000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54424994 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54409708 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
711895 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
640386 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
640386 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
365000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54424994 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
711895 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54409708 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
640386 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
7000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
709607000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4250000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200059000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153021000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
509555000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-148769000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
524173000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233982000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4764000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2591000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12016000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6147000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
20628000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
9530000 usd
us-gaap Operating Expenses
OperatingExpenses
55752000 usd
us-gaap Operating Expenses
OperatingExpenses
26202000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20628000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9530000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-55752000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-26202000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3147000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
8715000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 usd
CY2024Q3 bcax Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability
FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability
0 usd
CY2023Q3 bcax Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability
FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability
13328000 usd
bcax Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability
FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability
0 usd
bcax Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability
FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability
13356000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3147000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13315000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8715000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13343000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17481000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22845000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47037000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39545000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-17481000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22845000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47038000 usd
us-gaap Net Income Loss
NetIncomeLoss
-39545000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.60
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.60
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-38.23
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-38.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-70.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-70.18
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10901138 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10901138 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
597586 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
597586 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4174353 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4174353 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
563483 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
563483 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-98803000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
264000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7412000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-105908000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
352000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9288000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-114817000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
519000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22845000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-137111000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-148769000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1147000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12508000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-160080000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1315000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1038000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17049000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-174776000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
332429000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
367153000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
199000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2031000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-17481000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
509555000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47038000 usd
us-gaap Net Income Loss
NetIncomeLoss
-39545000 usd
bcax Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability
FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability
0 usd
bcax Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability
FairValueAdjustmentOfRedeemablePreferredStockAndFreestandingFinancialInstrumentLiability
13356000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4216000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1134000 usd
us-gaap Depreciation
Depreciation
41000 usd
us-gaap Depreciation
Depreciation
5000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
199000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
280000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
855000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-211000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44719000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37592000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
150000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
62000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
333479000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
bcax Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability
0 usd
bcax Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndFreestandingFinancialInstrumentLiability
77645000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1527000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
149000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
335006000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77794000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
290318000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
40052000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
230440000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4158000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
520758000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44210000 usd
bcax Settlement Of Freestanding Financial Instrument Liabilities
SettlementOfFreestandingFinancialInstrumentLiabilities
0 usd
bcax Settlement Of Freestanding Financial Instrument Liabilities
SettlementOfFreestandingFinancialInstrumentLiabilities
8001000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
703000 usd
bcax Vesting Of Early Exercise Stock Options
VestingOfEarlyExerciseStockOptions
51000 usd
bcax Vesting Of Early Exercise Stock Options
VestingOfEarlyExerciseStockOptions
51000 usd
bcax Offering Costs Incurred During Noncash Or Partial Noncash Transaction
OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
1052000 usd
bcax Offering Costs Incurred During Noncash Or Partial Noncash Transaction
OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
bcax Liability Upon Issuance Of Freestanding Financial Instrument
LiabilityUponIssuanceOfFreestandingFinancialInstrument
0 usd
bcax Liability Upon Issuance Of Freestanding Financial Instrument
LiabilityUponIssuanceOfFreestandingFinancialInstrument
642000 usd
us-gaap Nature Of Operations
NatureOfOperations
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Description of Business, Organization, and Liquidity</span><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Bicara Therapeutics Inc. (“Bicara” or the “Company”) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, Bicara will realize significant revenue from product sales.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Reverse Stock Split</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In September 2024, the Company’s board of directors approved an amendment to the fourth amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock and redeemable convertible preferred stock on a 9.2435-to-1 basis (the “Reverse Stock Split”) which was effected on September 5, 2024. The par value and authorized number of shares of common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All share data and per share data amounts for all periods presented in the condensed consolidated financial statements and notes thereto have been retrospectively adjusted to reflect the effect of the Reverse Stock Split.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Initial Public Offering ("IPO")</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">On September 13, 2024, the Company closed its IPO, pursuant to which it issued and sold an aggregate of 17,500,000 shares of its common stock at a public offering price of $18.00 per share and the Company issued and sold 2,625,000 additional shares of its common stock to the underwriters of the IPO pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of approximately $332.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company, totaling $29.8 million. Immediately prior to the closing of the IPO, the Company’s outstanding redeemable convertible preferred stock automatically converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">33,210,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> shares of common stock. Following the closing of the IPO, no shares of redeemable convertible preferred stock were authorized or outstanding.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In connection with the closing of its IPO, on September 13, 2024, the Company’s certificate of incorporation was amended and restated to authorize 500,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value of $0.0001 per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically has funded its operations from the issuance of redeemable convertible preferred stock, common stock and through debt financing.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of September 30, 2024, the Company had cash of $520.8 million and an accumulated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deficit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $200.1 million.</span></div>The Company expects that its cash and cash equivalents as of September 30, 2024 of $520.8 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.
CY2024Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
332400000 usd
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
29800000 usd
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
520800000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200100000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
520800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, the fair value of tranche right liabilities, and the fair values of common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div>
CY2024Q3 bcax Number Of Financial Institutions Cash And Cash Equivalents Held
NumberOfFinancialInstitutionsCashAndCashEquivalentsHeld
2 financialinstitution
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. At times, the Company’s cash deposits may be in excess of insured limits. Company has not experienced any losses on its deposits of cash and does not have off-balance sheet concentrations of credit risk.</span></div>
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15900000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6900000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43700000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20100000 usd
CY2024Q3 bcax Accrued Clinical Trial And Contract Manufacturing Expenses
AccruedClinicalTrialAndContractManufacturingExpenses
9200000 usd
CY2023Q4 bcax Accrued Clinical Trial And Contract Manufacturing Expenses
AccruedClinicalTrialAndContractManufacturingExpenses
9600000 usd
CY2024Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
332400000 usd
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
29800000 usd
CY2024Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
20125000 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
519631000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
230088000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
642000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
13356000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
8001000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5997000 usd
CY2023Q3 bcax Freestanding Financial Instrument Liability Current
FreestandingFinancialInstrumentLiabilityCurrent
6000000.0 usd
CY2022Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 bcax Number Of Members Board Of Directors
NumberOfMembersBoardOfDirectors
10 board_member
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 bcax Common Stock Voting Rights Number Of Directors Entitled To Be Elected
CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected
1 board_member
CY2023Q4 bcax Common Stock Voting Rights Number Of Directors Entitled To Be Elected
CommonStockVotingRightsNumberOfDirectorsEntitledToBeElected
1 board_member
CY2023 bcax Temporary Equity Protective Provision Affirmative Vote Percentage
TemporaryEquityProtectiveProvisionAffirmativeVotePercentage
0.65
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2031000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
519000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4216000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1134000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4850669 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3652807 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.13
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
393216 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
117494 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.01
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7992766 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
133789000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
897774 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16951000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
7992766 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.77
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
7094992 shares
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
37000000.0 usd
CY2023Q4 bcax Other Commitment Liability Refundable Deposit Amount
OtherCommitmentLiabilityRefundableDepositAmount
1900000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0002023658-24-000002-index-headers.html Edgar Link pending
0002023658-24-000002-index.html Edgar Link pending
0002023658-24-000002.txt Edgar Link pending
0002023658-24-000002-xbrl.zip Edgar Link pending
bcax-20240930.htm Edgar Link pending
bcax-20240930.xsd Edgar Link pending
exhibit311.htm Edgar Link pending
exhibit312.htm Edgar Link pending
exhibit321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_1.jpg Edgar Link pending
image_3.jpg Edgar Link pending
image_4.jpg Edgar Link pending
image_5.jpg Edgar Link pending
image_6.jpg Edgar Link pending
image_7.jpg Edgar Link pending
leaseagreement.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
bcax-20240930_def.xml Edgar Link unprocessable
bcax-20240930_lab.xml Edgar Link unprocessable
bcax-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcax-20240930_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcax-20240930_cal.xml Edgar Link unprocessable